A FibroGen Inc. investor filed suit in Delaware against current and former members of its board and management, claiming two of them sold millions in stock at inflated prices while the company used doctored data to hype an anemia drug being developed in partnership with
The lawsuit, made public Wednesday, accuses FibroGen’s senior leaders of pumping up its stock price by making false claims about clinical trial results supposedly showing the drug candidate to be highly safe and effective, before revelations of data manipulation tanked the company’s per-share value from $44 to $14 over a three-month period. ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.